Commitments and Contingencies - Additional Information (Detail)	1 Months Ended		3 Months Ended	12 Months Ended				3 Months Ended	1 Months Ended		12 Months Ended	3 Months Ended
	Jun. 30, 2014 USD ($)	Jul. 31, 2013 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2014 EUR (€)	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2014 Maximum [Member] USD ($)	Sep. 30, 2014 SRI Litigation [Member] USD ($)	Jun. 30, 2014 SRI Litigation [Member] USD ($)	Sep. 30, 2014 Patents [Member]	Sep. 30, 2013 Prior to Fiscal 2013 [Member] USD ($)
Commitments and Contingencies [Line Items]
Additional litigation expense within discontinued operations	$ 300,000								$ 100,000	$ 100,000
Unreimbursed legal expenses		1,300,000
Payment received on unreimbursed legal expenses			1,000,000
Reimbursement of legal fee, Percentage						75.00%
Legal expenses												600,000
Additional shares of common stock to stockholders				480,059	480,059
License agreement commencement date				2006-03	2006-03
Annual minimum payments for licenses				254,000	200,000
Exchange rate relating to license payment				$ 1.2682
Future minimum payments associated with license				3,300,000
Patent expiry date											2027-09
Additional maximum amount payable on successful achievement of specified milestones to sellers of PR Pharma				2,500,000
Indemnification period				5 years	5 years
Rights to receive contingent consideration								100,000
Rent expense related to operating leases				$ 100,000		$ 100,000	$ 100,000